A PHASE one clinical trial led by Monash University to assess the safety and performance of a novel oxytocin inhaler in healthy, non-pregnant female volunteers has commenced in Melbourne.
The Inhaled Oxytocin Project, led by Prof Michelle McIntosh from the Monash Institute of Pharmaceutical Sciences, has developed a heat-stable powder formulation of oxytocin that, when inhaled, aims to provide protection against postpartum haemorrhage comparable to existing gold standard injection products.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 May 23
